Cite
Response of a chemo-resistant triple-negative breast cancer patient to a combination of p62-encoding plasmid, Elenagen, and CMF chemotherapy
MLA
Sergey I. Kolesnikov, et al. “Response of a Chemo-Resistant Triple-Negative Breast Cancer Patient to a Combination of P62-Encoding Plasmid, Elenagen, and CMF Chemotherapy.” Oncotarget, vol. 11, no. 3, Jan. 2020, pp. 294–99. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....11742ab79090fcf4c2a2bdcb47711195&authtype=sso&custid=ns315887.
APA
Sergey I. Kolesnikov, Alexander M. Shneider, Vladimir L. Gabai, Albert Sufianov, & Dmitry M. Ponomarenko. (2020). Response of a chemo-resistant triple-negative breast cancer patient to a combination of p62-encoding plasmid, Elenagen, and CMF chemotherapy. Oncotarget, 11(3), 294–299.
Chicago
Sergey I. Kolesnikov, Alexander M. Shneider, Vladimir L. Gabai, Albert Sufianov, and Dmitry M. Ponomarenko. 2020. “Response of a Chemo-Resistant Triple-Negative Breast Cancer Patient to a Combination of P62-Encoding Plasmid, Elenagen, and CMF Chemotherapy.” Oncotarget 11 (3): 294–99. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....11742ab79090fcf4c2a2bdcb47711195&authtype=sso&custid=ns315887.